Investor List:

Top Therapeutics Series B Investors in San Francisco Bay Area (14)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Manufacturing (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Manufacturing (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Manufacturing (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Eric Weinstein, Managing Director at Thiel Capital
Eric Weinstein
Thiel Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $1.5M
Investors in San Francisco (CA)
Photo of Soyoung Park, General Partner at 1004 Venture Partners
Soyoung Park
1004 Venture Partners·General Partner
Sweet spot: $500K
Range: $100K - $10.0M
Investors in Asia, Investors in Boston / New England, Investors in SF Bay Area (CA), Investors in Europe, Investors in United Kingdom, Investors in United States
Investors in Wellness & Fitness (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Generative Tech/AI (Seed), Investors in Wellness & Fitness (Seed), Investors in Therapeutics (Seed), Investors in Robotics (Seed), Investors in Medical Devices (Seed), Investors in Consumer Health (Seed), Investors in Therapeutics (Seed), Investors in Generative Tech/AI (Seed), Investors in Digital Health (Seed), Investors in Diagnostics (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Generative Tech/AI (Seed), Investors in Consumer Health (Seed), Investors in Wellness & Fitness (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Health IT (Seed), Investors in Robotics (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Robotics (Seed), Investors in Diagnostics (Seed), Investors in Medical Devices (Seed), Investors in Consumer Health (Seed), Investors in Therapeutics (Series A), Investors in Wellness & Fitness (Series A), Investors in Diagnostics (Series A), Investors in Generative Tech/AI (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Robotics (Series A), Investors in Medical Devices (Series A), Investors in Wellness & Fitness (Series A), Investors in Consumer Health (Series A), Investors in Generative Tech/AI (Series A), Investors in Medical Devices (Series A), Investors in Digital Health (Series A), Investors in Diagnostics (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Robotics (Series A), Investors in Wellness & Fitness (Series A), Investors in Generative Tech/AI (Series A), Investors in Consumer Health (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Health IT (Series A), Investors in Digital Health (Series A), Investors in Consumer Health (Series A), Investors in Health IT (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Robotics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Wellness & Fitness (Series B), Investors in Therapeutics (Series B), Investors in Wellness & Fitness (Series B), Investors in Generative Tech/AI (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Robotics (Series B), Investors in Medical Devices (Series B), Investors in Diagnostics (Series B), Investors in Consumer Health (Series B), Investors in Medical Devices (Series B), Investors in Digital Health (Series B), Investors in Generative Tech/AI (Series B), Investors in Wellness & Fitness (Series B), Investors in BioTech (Series B), Investors in Robotics (Series B), Investors in Health IT (Series B), Investors in Generative Tech/AI (Series B), Investors in Consumer Health (Series B), Investors in Medical Devices (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Robotics (Series B), Investors in Consumer Health (Series B), Investors in Boston / New England (Other Lists), Investors in San Francisco Bay Area (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in Diverse Investors (Other Lists), Investors in Female Investors (Other Lists)
Photo of Dan Becker, Managing Director at Access Biotechnology
Dan Becker
Access Biotechnology·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Mateo (CA), Investors in New York (NY)
Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in BioTech (Series B), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Sangwoo Lee, Managing Director at Korea Investment Partners
Sangwoo Lee
Korea Investment Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Mountain View (CA)
Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in BioTech (Series B), Investors in San Francisco Bay Area (Other Lists)
Photo of Timothy Van Voris, Managing Director at Thiel Capital
Timothy Van Voris
Thiel Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $1.5M
Investors in San Francisco (CA)
Photo of David Malek, Venture Partner at Pivotal bioVenture Partners
David Malek
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA)
Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in BioTech (Series B), Investors in BioTech (Series B), Investors in San Francisco Bay Area (Other Lists)
Photo of Blake Masters, Principal at Thiel Capital
Blake Masters
Thiel Capital·Principal
Sweet spot: $1.5M
Range: $100K - $1.5M
Investors in San Francisco (CA), Investors in Tucson (AZ), Investors in Los Angeles (CA)
Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Pharmaceuticals (Seed), Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in Manufacturing (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Therapeutics (Series A), Investors in Manufacturing (Series A), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Manufacturing (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in Manufacturing (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Therapeutics (Series B), Investors in Manufacturing (Series B), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in San Francisco Bay Area (Other Lists)